Managers / Q2 2021 · view latest →
Krensavage Asset Management, LLC
CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582
Summary
Krensavage Asset Management, LLC reported $295M in U.S.-listed holdings across 13 positions for Q2 2021.
Its largest position, REGN, represents 15.6% of the portfolio.
Compared with Q1 2021, the fund opened 2 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 86.7% · $255M
- Other · 13.3% · $39M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| EGRXEAGLE PHARMACEUTICALS INC | NEW | +70.8K | 70.8K | +$3M | $3M |
| TVTXTRAVERE THERAPEUTICS INC | NEW | +140.0K | 140.0K | +$2M | $2M |
| ALXNALEXION PHARMACEUTICALS INC | SOLD OUT | −6.9K | 0 | −$1M | $0 |
| ANABANAPTYSBIO INC | TRIMMED | −14.8K | 10.9K | −$272,000 | $282,000 |
| BIIBBIOGEN INC | TRIMMED | −41.0K | 97.5K | −$5M | $34M |
| UTHRUNITED THERAPEUTICS CORP | TRIMMED | −29.7K | 219.7K | −$2M | $39M |
| ENTAENANTA PHARMACEUTICALS INC | ADDED | +76.8K | 939.6K | −$1M | $41M |
| ALKSALKERMES PLC | HELD | +61.5K | 1.69M | +$11M | $41M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | REGNREGENERON PHARMACEUTICALShistory → | COM | 15.57% | $46M | 82.1K |
| 2 | ALKSALKERMES PLChistory → | COM | 14.06% | $41M | 1.69M |
| 3 | ENTAENANTA PHARMACEUTICALS INChistory → | COM | 14.04% | $41M | 939.6K |
| 4 | UTHRUNITED THERAPEUTICS CORPhistory → | COM | 13.38% | $39M | 219.7K |
| 5 | TARO PHARMACEUTICAL INDUS | COM | 13.28% | $39M | 543.7K |
| 6 | BIIBBIOGEN INChistory → | COM | 11.46% | $34M | 97.5K |
| 7 | MCKMCKESSON CORPhistory → | COM | 10.81% | $32M | 166.4K |
| 8 | SURGALIGN HOLDINGS INC | COM | 3.02% | $9M | 6.40M |
| 9 | INVACARE CORP | COM | 2.47% | $7M | 901.7K |
| 10 | EGRXEAGLE PHARMACEUTICALS INChistory → | COM | 1.03% | $3M | 70.8K |
| 11 | TVTXTRAVERE THERAPEUTICS INC | COM | 0.69% | $2M | 140.0K |
| 12 | ANABANAPTYSBIO INC | COM | 0.10% | $282,000 | 10.9K |
| 13 | NEXTCURE INC | COM | 0.09% | $252,000 | 31.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $256M | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $283M | 18 | Feb 18, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $235M | 17 | Nov 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $189M | 15 | Aug 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $181M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $169M | 12 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2024 | $178M | 13 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $218M | 13 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $226M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $282M | 12 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 12 | Nov 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $316M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $329M | 12 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $324M | 12 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $314M | 14 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $302M | 14 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 13 | May 17, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $288M | 10 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $319M | 13 | Nov 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $295M | 13 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $289M | 12 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $342M | 12 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $314M | 11 | Dec 8, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $368M | 11 | Aug 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2020 | $311M | 13 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $293M | 12 | Feb 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $260M | 10 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 10 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $370M | 12 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.